Clinical trials: Advanced Cancer
Breast Cancer Female, Ovarian Cancer
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
Safety and tolerability of combination of Nivolumab and Ipilimumab will be studied in patients with 3 different types of cancers in 3 parts of the study, as shown below: Part 1 - Neoadjuvant Therapy of Breast Cancer; Part 2 …
- Conditions
- Breast Cancer Female, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03342417
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- ExcellaBio LLC
Head and Neck Neoplasms
Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors
This study will investigate the efficacy and safety of recombinant human endostatin adenovirus combined with chemotherapy for advanced head and neck malignant tumors.
- Trial name
- NCT02283489
- Testing
- recombinant human endostatin adenovirus, Cisplatin injection, Paclitaxel injection
- Where
- 4 sites in China
- Volunteers
- 180 people
- Sponsor
- Renmiao Zhang
Locally Advanced Head-and-Neck Cancer
Carbon Ion Re-Radiotherapy in Patients With Recurrent or Progressive Locally Advanced Head-and-Neck Cancer
After multimodal therapy of head-and-neck tumors, patients often develop local recurrence, locally progressive disease or second primary tumors. In this highly pre-treated patient cohort, therapeutic options are limited.
- Trial name
- CARE (NCT04185974)
- Testing
- C12 re-irradiation, Photon re-irradiation
- Where
- 2 sites in Germany
- Volunteers
- 72 people
- Sponsor
- University Hospital Heidelberg
CRC
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
This is a non-randomized, open-label, dose-escalation and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, and efficacy of HCB101 in combination with Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in…
- Trial name
- NCT07204574
- Testing
- HCB101, Bevacizumab, Cetuximab (Erbitux)
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Refractory Cancer, Recurrent Cancer
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
This study will evaluate the safety, tolerability, and pharmacokinetics of RO7617991, and will make a preliminary assessment of the anti-tumor activity of RO7617991 in human leukocyte antigen (HLA)-A*02 eligible patients with…
- Conditions
- Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- Trial name
- NCT06372574
- Testing
- RO7617991, Tocilizumab
- Sponsor
- Genentech, Inc.
Malignant Solid Tumour, Liver Metastases
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
A pharmacodynamic study to evaluate the effect of AV-299 on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases.
- Trial name
- NCT00969410
- Testing
- AV-299
- Where
- Spain
- Volunteers
- 19 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Advanced Solid Tumors
Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
A Study of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) Therapy for Patients With Advanced Solid Tumors
- Trial name
- NCT07106814
- Testing
- Metabolically Armed TIL cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Anhui Provincial Hospital
Colorectal Cancer, Non-Small Cell Lung Cancer
A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)
This is an observational study designed to follow patients with metastatic or locally advanced and unresectable CRC or locally advanced or metastatic NSCLC (excluding predominant squamous histology) who are receiving Avastin in…
- Trial name
- ARIES (NCT00388206)
- Volunteers
- 3,998 people
- Sponsor
- Genentech, Inc.
Esophageal Cancer, Gastric Cancer
S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as triacetyluridine may protect normal cells from the side effects of…
- Trial name
- NCT00004233
- Testing
- fluorouracil, leucovorin calcium, triacetyluridine
- Where
- 97 sites in United States
- Volunteers
- 65 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Breast Cancer
Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer
Phase IV trial to investigate the effect of the combination of Letrozole with trastuzumab in metastatic breast cancer patients
- Trial name
- eLEcTRA (NCT00171847)
- Testing
- Letrozole, Trastuzumab plus Letrozole
- Where
- Germany
- Volunteers
- 93 people
- Sponsor
- Novartis Pharmaceuticals
Advanced and/or Metastatic Solid Organ Cancer
A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer
Aim of the study is to evaluate the safety and find the maximal tolerated dose of VB-111 in Patients with Advanced Metastatic Cancer
- Trial name
- NCT00559117
- Testing
- VB-111
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Advanced Colorectal Cancer, Adenocarcinoma of the Colon
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
To determine the effect of ABT-869 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 on disease progression in advanced colorectal cancer.
- Conditions
- Advanced Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- NCT00707889
- Testing
- ABT-869, bevacizumab, oxaliplatin
- Where
- 46 sites in United States, Australia and 12 more
- Volunteers
- 159 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Non-small Cell Lung Cancer
Analysis of Soluble Mediators,Cytokines and FACs as Prognostic Factors in Advanced Non-squamous Lung Carcinoma
Recent studies have shown that the assessment of a set of cytokines and / or circulating angiogenic factors (FACs) could be used to identify prognostic factors predictive of efficacy and / or potential mechanisms of resistance to…
- Trial name
- NCT03156868
- Where
- 25 sites in Spain
- Volunteers
- 153 people
- Sponsor
- Spanish Lung Cancer Group
Non Small Cell Lung Cancer
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants.
- Trial name
- NCT01017874
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 12 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 236 people
- Sponsor
- Eli Lilly and Company
Esophageal Squamous Cell Carcinoma, Enteral Nutrition Therapy
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
This is a randomized, prospective, multicenter study.
- Conditions
- Esophageal Squamous Cell Carcinoma, Enteral Nutrition Therapy, Chemoradiotherapy
- Trial name
- NCT02399306
- Testing
- Enteral nutrition, radiotherapy
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Squamous Cell Carcinoma, the Nasal Cavity
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
This is a single arm phase II study that will evaluate the combination of pembrolizumab, docetaxel, and cisplatin or carboplatin (PDC) as single treatment modality in patients with stage II-IVb (T2-4, any N, M0) squamous cell…
- Conditions
- Squamous Cell Carcinoma, the Nasal Cavity, Paranasal Sinuses
- Trial name
- NCT05027633
- Testing
- Pembrolizumab, Docetaxel, Cisplatin
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors
- Trial name
- NCT07524348
- Testing
- E303
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 149 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Non-small Cell Lung Cancer
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose
To determine whether dose escalation can provide a better survival to patients who failed with icotinib at routine dose.
- Trial name
- NCT01465243
- Testing
- Icotinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Gastric Cancer, RCT
Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
The purpose of this clinical trial is to evaluate whether perioperative ivonescimab in combination with S-1 and oxaliplatin (SOX) is effective in treating locally advanced gastric or gastroesophageal junction (GEJ)…
- Trial name
- Huaxi (NCT07374250)
- Testing
- Ivonescimab (20mg/kg Q3W), Oxaliplatin, S-1
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Sichuan University
Carcinoma, Hepatocellular
Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
To compare the overall survival of thalidomide- and placebo-treated advanced HCC patients.
- Trial name
- NCT00225290
- Testing
- Thalidomide(Thado)
- Where
- Taiwan
- Volunteers
- 230 people
- Sponsor
- TTY Biopharm